Keywords: transition, fully, enrolled, gastrin, analog, trial, canada

Transition fully enrolled for gastrin analog trial

Article | 09 February 2009

Print This

Canada's Transition Therapeutics has completed patient enrolment for a Phase II study of its gastrin analog, TT-223, in patients with ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in